Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study

Figure 3 Kaplan-Meier survival curves of all-cause graft survival, death-censored graft survival and recipient survival in patients who received alemtuzumab vs recipients of basiliximab induction. A: All-cause graft survival; B: Death-censored graft survival; C: Recipient survival. Data derived from a propensity-matched cohort (events = allograft loss and death with functioning graft; allograft loss censored for death and recipient death with functioning graft, respectively). ACGS: All-cause graft survival; DCGS: Death-censored graft survival; RS: Recipient survival.